July 6, 2021
Sagent Pharmaceuticals, a US subsidiary of Nichi-Iko Pharmaceutical, has called off the development of the protease inhibitor camostat mesilate for the treatment of COVID-19 after it failed to hit the main goal in a PII study. Nichi-Iko said on July...read more